Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page
- Check3 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study details with a standard error page and a minimal site footer. This indicates restricted access to the ClinicalTrials.gov study record for NCT02982720.SummaryDifference19%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now displays a new Revision: v3.6.6 label, indicating a minor build/version update.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, reflecting a backend/page update.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page’s revision number has been updated from v3.6.3 to v3.6.4. This change represents a minor site release with no impact on the study details or visible content.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous Revision: v3.6.2. This reflects a minor update to the page’s version history.SummaryDifference0.1%

- Check89 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0, indicating a site version update. This metadata change does not alter the study details or how users interact with the page.SummaryDifference0.1%

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.